DXR Daxor Corp.

Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl

Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
EN
12/10/2020

Underlying

DXRDaxor Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Daxor Corp.

 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in T...

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment  Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care setting, driving clinic...

February 24, 2026 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation Announces Transition To Securities Exchange Act of 1...

Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the “Exchange Act”), subject to its completion of required regulatory filings and approvals. This transition re...

February 10, 2026 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation Announces $9 Million Registered Direct Offering

Daxor Corporation Announces $9 Million Registered Direct Offering OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Company are expected t...

January 23, 2026 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of...

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its Blood Volume Analysis (BVA) platform into three new, prestigious facilities. This milestone demonstrates the accelerating market adoption of BVA's pivotal role in precision fluid management, leading to improved patient outcomes ...

November 25, 2025 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Gro...

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York City. Mr. Feldschuh will be a...

October 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch